Bioceramics 2014 Technical Program
The meeting consists of four plenary talks, eight panel discussions, and a rapid-fire presentation and poster session. Each panelist will give a 5-minute introductory statement about his/her area of expertise and technology of interest, then a moderator will lead a Q &A with the audience.
|Thursday, July 31, 2014|
Plenary Session I
Affordable healthcare? Role of bioceramic technology, Larry Hench, professor, Florida Institute of Technology, and inventor of Bioglass®, USA
Orthopedics I Panel Discussion
This session discusses new and emerging bioceramic technologies and technologies that are in the commercial pipeline. It will focus on bioceramics with orthopedic applications, including cranial, facial, orthopedic, bone void fillers, and spinal applications. Individual panelists will discuss the many used of bioactive glass for the treatment of bone injuries and bone defects in the body. It will explore material properties and forms along with dynamic bioactive bone graft material that can be molded into desired shapes for implantation.
- Zehra Tosun, senior R&D biomedical engineer, NovaBone Products LLC
- Charanpreet S. Bagga, president and CEO, Prosidyan, Inc.
- Markus Reiterer, senior principal scientist, Corp. Core Technologies, Medtronic, Inc.
- David Dean, associate professor, college of medicine, The Ohio State University
New Technologies Panel Discussion
This session focuses on emerging technologies containing bioceramics covering wound care, bone grafting, drug delivery and coatings. Specific topics include emerging topics of bioactive glasses, including new frontiers in wound care and bone grafting. In addition drug delivery will be discussed including nanoparticulate alternatives for drug delivery, porous silica microspheres for medical applications, and coating technologies for medical implants.
- James H. Adair, CSO, Keystone Nano, Inc.; professor, Pennsylvania State University
- George G. Wicks, president, Wicks Consulting Services
- Orville Bailey, president, Covalent Coatings Technologies, LLC
- Jacob J. Stiglich, Ultramet, Inc.
Plenary Session II
The current regulatory environment, Glenn Stiegman, vice president, regulatory affairs, Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA), USA
Regulatory, Patents and Intellectual Property Panel Discussion
This panel discussion focuses on the current regulatory environment, Food and Drug Administration trends, how to obtain and maintain compliance, patent trends and protecting intellectual property.
- Aditya Sukthankar, regulatory consultant, mdi Consultants Inc.
- Tram Nguyen, partner, MH2 Technology Law Group
- Glenn Stiegman, vice president, regulatory affairs, Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA)
Radiotherapeutics Panel Discussion
This panel discussion focuses on clinical efficacy of tenured products along with new treatment options from emerging technologies and applications. Panelists will discuss product development, materials requirements, properties of good radiotherapeutic materials, chemical durability, how to maximize specific activity, method of activation and the right type of radioisotope.
- Wayne Mullet, director of development, BTG International Canada Inc.
- Delbert Day, Curators’ Professor Emeritus of Materials Science & Engineering, Missouri University of Science and Technology
|Friday, August 1, 2014|
Plenary Session III
Bone graft alternatives for complex spine surgery – What I need in the OR, Dr. Safdar Khan, MD, chief, division of spine, The Ohio State University, USA
Clinical Testing Panel Discussion
This panel discussion focuses on the efficacy of a multitude of products from a variety of medical fields and how these products may be improved to get an improved outcome. Panelists will cover preliminary and primary research, testing required for commercialization, and clinical trials.
- Ben Tempel, CEO, NanOphthalmics
- Dr. Safdar Khan, MD, chief, division of spine, The Ohio State University
Bioceramic Testing Panel Discussion
This panel discussion focuses on test methods currently used for evaluating bioceramics, especially in-vitro and cellular biology. The panelists will also discuss which animal models to use for acceptance by regulatory groups for specific indications of treatment.
- David Greenspan, president, Spinode Consulting
- Steve Jung, chief technology officer, Mo-Sci Corp.
- Larry Hench, professor, Florida Institute of Technology
Plenary Session IV
Surgical trends, Dr. Hyun Bae, MD, surgeon, The Spine Institute, USA
Orthopedics II Panel Discussion
This follow-up session to Orthopedics I discusses new and emerging bioceramic technologies and technologies that are in the commercial pipeline. Individual panelists will discuss collagen ceramic products engineered to mimic the composition and pore structure of natural human bone along with bioactive bone graft materials that undergoes a time dependent surface modification upon implanting in living tissue eventually resulting the formation of new bone.
- Sunil Saini, director, R&D, Integra Lifesciences
- John Brunelle, chief technology officer, BioStructures LLC
- David Hill, associate professor, department of anatomy and cell biology, Georgia Regents University
- Dr. Hyun Bae, MD, surgeon, The Spine Institute
Dental Applications Panel Discussion
This panel discussion focuses on new and emerging bioceramic technologies and technologies that are in the commercial pipeline with dental applications.
- Carolyn Primus, Primus Consulting
- Gregory Pomrink, vice president, research & development, NovaBone Products LLC